Home > About

About us

Board of Directors

Dr Cherrell Hirst
Chair

Board of Directors

Dr Cherrell Hirst
AO FTSE MBBS BEdSt D.Univ (Hon)
Chair
Dr Hirst has had a distinguished clinical career in the detection and diagnosis of breast cancer and extensive and respected achievements as a director of multiple commercial, government and not-for-profit organisations including as Chancellor of QUT from 1994-2004. Dr Hirst is currently Chair of ImpediMed Ltd and a director of Medibank Private Ltd, Gold Coast Hospital and Health Service and RSLCare and in addition she chairs the Advisory Board of the Institute of Molecular Biosciences at UQ. She has previously been a director of Hatchtech, Peplin, Suncorp and Avan amongst others.
Timothy Hughes
Non-Executive Director

Board of Directors

Timothy Hughes
BSc (Hons) BA (Hons) M.NatRes
Non-Executive Director
Mr Timothy Hughes has over 30 years’ experience in senior roles in the investment management and investment banking industries. Mr Hughes previously served in roles including Chief Investment Officer at Rothschild Australia, Value Capital Management and Catholic Super, and was an economics and investment columnist for the Courier-Mail for 17 years. Mr Hughes currently sits on the Investment Advisory Panel of HESTA, one of Australia’s largest super funds, and is on the Advisory Board of the Centre for Investor Education.
Dr Christian Behrenbruch
Non-Executive Director

Board of Directors

Dr Christian Behrenbruch
B.Eng (Hons) MBA D.Phil (Oxon) JD GAICD
Non-Executive Director
Dr Christian Behrenbruch has over 15 years of healthcare executive leadership experience. He previously served in CEO (and executive director) appointments at Mirada Solutions, CTI Molecular Imaging (now Siemens), Fibron Technologies and ImaginAb, Inc. He is a former director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and Cell Therapies P/L (a partnership with the Peter MacCallum Cancer Centre). Dr Behrenbruch is currently a member of the Monash Engineering Foundation Board and holds adjunct appointments at Monash University and RMIT University.
John Michailidis
Non-Executive Director

Board of Directors

John Michailidis
B.Sc EMBA (Harv) MAICD FAIM
Non-Executive Director
Mr. Michailidis is currently the Managing Director for TEVA Australia/NZ and brings almost 30 years of commercial pharmaceutical experience to Factor. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman – La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). Mr. Michailidis holds a BSc in Genetics from LaTrobe University, and executive business qualifications from Harvard Business School and INSEAD.
Dr Robert Ryan
Non-Executive Director

Board of Directors

Dr Robert Ryan
B.Sc MS Ph.D DABT
Non-Executive Director
Dr. Ryan has more than 27 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV, and covering senior preclinical, regulatory and clinical activities with Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, and Pfizer. Dr. Ryan is currently the President and CEO of Innova Therapeutics, a company focused on developing innovative therapies for diseases with high unmet needs. Prior to Innova, Dr. Ryan was the President and CEO of Scioderm, where he led the development of SD-101, a topical therapy for Epidermolysis Bullosa. Scioderm was the first biotech to receive “Breakthrough Therapy” designation from the FDA, and the company was sold in 2015 to Amicus Therapeutics, with upfront payments and milestones totaling approximately $957 million. Dr Ryan has direct product development experience that has resulted in the approval of over 20 drug candidates in various therapeutic areas. Dr. Ryan graduated with a doctorate degree in Toxicology from the University of North Carolina at Chapel Hill, MS degrees in Pharmacokinetics and Genetics, and is a Diplomate of the American Board of Toxicology.